Image Analysis Group (IAG), a company specializing in clinical trial imaging and AI-driven biomarkers, has enhanced its footprint in the United States by inaugurating a new office in Cambridge, Massachusetts. This strategic location in the Boston area positions IAG closer to key biotechnology and pharmaceutical firms, facilitating the strengthening of partnerships and the provision of enhanced local support for clinical trials throughout the region.
The Cambridge office plays a crucial role in supporting IAG’s comprehensive work across various therapeutic fields such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. The proximity to sponsors and contract research organizations enables IAG to engage more effectively in Phase I–III clinical trials and imaging-intensive development programs. Additionally, the company intends to stimulate job growth in the area by recruiting for roles in clinical imaging operations, data science, regulatory support, and business development within the next 12 to 24 months.
IAG’s new office is set to bolster the company’s end-to-end imaging services, which include clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery. By embedding itself within the Boston life-sciences ecosystem, IAG aims to enhance its collaboration efforts with biotechnology entities, pharmaceutical firms, academic bodies, and clinical research centers.
Operating on a global scale, IAG provides support for clinical trials across North America, Europe, and Asia-Pacific. The company collaborates with pharmaceutical, biotechnology, and medtech firms, as well as contract research organizations (CROs), to conduct multi-center studies. Its international operations are geared towards delivering standardized imaging protocols, centralized data harmonization, and consistent imaging analysis across global trials.
Founded in 2007 and headquartered in London, Image Analysis Group acts as an imaging Clinical Research Organization (iCRO), assisting pharmaceutical, biotechnology, and medical technology companies in achieving imaging-based clinical trial endpoints. The company’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time oversight of clinical trials.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.
